Published in Tidsskr Nor Laegeforen on October 16, 2017
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med (2010) 8.10
Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med (2006) 6.04
Retracted The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med (2004) 3.22
Gene expression patterns in ovarian carcinomas. Mol Biol Cell (2003) 2.55
Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology (2009) 1.91
PIK3CA mutations in advanced ovarian carcinomas. Hum Mutat (2005) 1.61
Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One (2011) 1.57
Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial. Eur J Cancer (2010) 1.57
TCTP is an androgen-regulated gene implicated in prostate cancer. PLoS One (2013) 1.45
Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer. BMC Genomics (2006) 1.37
Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J Clin Microbiol (2006) 1.36
Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res (2005) 1.22
Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma. Cancer (2004) 1.22
Gene dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis and chemoradioresistance of cervical cancer. PLoS Genet (2009) 1.19
GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data. Genome Biol (2008) 1.18
Diagnosis and treatment of sarcoma of the uterus. A review. Acta Oncol (2012) 1.16
EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis (2003) 1.13
Concern Gross genomic aberrations in precancers: clinical implications of a long-term follow-up study in oral erythroplakias. J Clin Oncol (2002) 1.10
Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: how well do physicians' assessments agree with those of their patients? Int J Radiat Oncol Biol Phys (2008) 1.10
The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas. Gynecol Oncol (2005) 1.09
The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma. Gynecol Oncol (2006) 1.09
Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer. Cancer Res (2007) 1.07
beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients. Eur J Cancer (2005) 1.06
Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis. Gynecol Oncol (2003) 1.06
Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma. Gynecol Oncol (2004) 1.03
Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI. Cancer Res (2012) 1.02
Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas. Am J Clin Pathol (2005) 0.99
Metabolic mapping by use of high-resolution magic angle spinning 1H MR spectroscopy for assessment of apoptosis in cervical carcinomas. BMC Cancer (2007) 0.98
Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. Clin Cancer Res (2006) 0.97
Genomic aberration patterns and expression profiles of squamous cell carcinomas of the vulva. Genes Chromosomes Cancer (2013) 0.96
Identification of eight candidate target genes of the recurrent 3p12-p14 loss in cervical cancer by integrative genomic profiling. J Pathol (2013) 0.95
High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection. BMC Clin Pharmacol (2006) 0.94
The mitogen-activated protein kinase phosphatase vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer. Cancer Res (2008) 0.94
STAMP1 is both a proliferative and an antiapoptotic factor in prostate cancer. Cancer Res (2010) 0.93
Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas. Mod Pathol (2006) 0.91
Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Hum Mutat (2004) 0.91
Large scale genomic instability as an additive prognostic marker in early prostate cancer. Cell Oncol (2009) 0.90
Intratumor chromosomal heterogeneity in advanced carcinomas of the uterine cervix. Int J Cancer (2004) 0.90
Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients. Mol Cancer (2005) 0.89
Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma. Cancer (2005) 0.89
Prognostic value of adaptive textural features--the effect of standardizing nuclear first-order gray level statistics and mixing information from nuclei having different area. Cell Oncol (2006) 0.89
Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. Proc Natl Acad Sci U S A (2013) 0.89
Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors. Neuro Oncol (2009) 0.89
The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions. Clin Exp Metastasis (2004) 0.88
Low dimensional adaptive texture feature vectors from class distance and class difference matrices. IEEE Trans Med Imaging (2004) 0.88
Membranous expression of ectodomain isoforms of the epidermal growth factor receptor predicts outcome after chemoradiotherapy of lymph node-negative cervical cancer. Clin Cancer Res (2011) 0.88
Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome. Radiother Oncol (2013) 0.88
Long-term outcomes after pelvic radiation for early-stage endometrial cancer. J Clin Oncol (2013) 0.87
PIKfyve, MTMR3 and their product PtdIns5P regulate cancer cell migration and invasion through activation of Rac1. Biochem J (2014) 0.87
Beta-catenin expression in uterine sarcomas and its relation to clinicopathological parameters. Eur J Cancer (2009) 0.87
Retracted Cyclooxygenase-2 (COX-2) expression in high-risk premalignant oral lesions. Oral Oncol (2003) 0.87
The sexual activity questionnaire: pychometric properties and normative data in a norwegian population sample. J Womens Health (Larchmt) (2007) 0.86
Risk grouping in stage IB squamous cell cervical carcinoma. Gynecol Oncol (2005) 0.85
Adenomas and follicular carcinomas of the thyroid display two major patterns of chromosomal changes. J Pathol (2005) 0.85
[Fine needle cytology of the thyroid gland]. Tidsskr Nor Laegeforen (2004) 0.84
Retracted Molecular based treatment of oral cancer. Oral Oncol (2003) 0.84
Dynamic contrast-enhanced MRI of cervical cancers: temporal percentile screening of contrast enhancement identifies parameters for prediction of chemoradioresistance. Int J Radiat Oncol Biol Phys (2011) 0.84
Late effects after radiotherapy for locally advanced cervical cancer: comparison of two brachytherapy schedules and effect of dose delivered weekly. Int J Radiat Oncol Biol Phys (2009) 0.83
Automatic segmentation of cell nuclei in Feulgen-stained histological sections of prostate cancer and quantitative evaluation of segmentation results. Cytometry A (2012) 0.83
Prognostic significance of dysadherin expression in cervical squamous cell carcinoma. Pathol Oncol Res (2004) 0.83
Caveolin-1 expression in ovarian carcinoma is MDR1 independent. Am J Clin Pathol (2002) 0.83
Pharmacokinetic analysis and k-means clustering of DCEMR images for radiotherapy outcome prediction of advanced cervical cancers. Acta Oncol (2011) 0.82
High levels of genomic aberrations in serous ovarian cancers are associated with better survival. PLoS One (2013) 0.82
E-cadherin and catenins in early squamous cervical carcinoma. Gynecol Oncol (2004) 0.82
Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions. Clin Exp Metastasis (2002) 0.82
Expressions of EphA2 and EphrinA-1 in early squamous cell cervical carcinomas and their relation to prognosis. Int J Med Sci (2008) 0.81
DNA ploidy heterogeneity in endometrial carcinoma: comparison between curettage and hysterectomy specimens. Int J Gynecol Pathol (2010) 0.81
Multiple chromosomal monosomies are characteristic of giant cell ependymoma. Hum Pathol (2011) 0.81
The prognostic value of adaptive nuclear texture features from patient gray level entropy matrices in early stage ovarian cancer. Anal Cell Pathol (Amst) (2012) 0.80
Human papillomavirus DNA and e6/e7 mRNA status in relation to survival of patients treated for cervical squamous cell carcinoma. Open Virol J (2008) 0.80
Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy. Gynecol Oncol (2013) 0.80
Fine-needle aspiration cytology of the thyroid gland: comparative analysis of experience at three hospitals. Diagn Cytopathol (2006) 0.80
Consistent numerical chromosome aberrations in thecofibromas of the ovary. Virchows Arch (2008) 0.79
European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and pharmaceutical companies. Int J Gynecol Cancer (2010) 0.79
Expression of the 67 kDa laminin receptor and the alpha6 integrin subunit in serous ovarian carcinoma. Clin Exp Metastasis (2003) 0.79
Phosphorylation of EGFR measured with in situ proximity ligation assay: relationship to EGFR protein level and gene dosage in cervical cancer. Radiother Oncol (2011) 0.79
Cyclins and proliferation markers in early squamous cervical carcinoma. Gynecol Oncol (2004) 0.79
Initial experience in a cancer hospital in Nepal with sentinel lymph node mapping and biopsy for evaluation of axillary lymph node status in palpable invasive breast cancer. Nepal Med Coll J (2007) 0.79
X chromosome inactivation in cervical cancer patients. Cancer Genet Cytogenet (2003) 0.79
Intestinal malabsorption in long-term survivors of cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys (2008) 0.78
Entropy-based adaptive nuclear texture features are independent prognostic markers in a total population of uterine sarcomas. Cytometry A (2014) 0.78
Expression of 14-3-3sigma in cervical squamous cell carcinomas: relationship with clinical outcome. Oncol Rep (2009) 0.77
Evaluation of genomic changes in a large series of malignant ovarian germ cell tumors--relation to clinicopathologic variables. Cancer Genet Cytogenet (2004) 0.77
Ovarian carcinoma cells in effusions show increased S-phase fraction compared to corresponding primary tumors. Diagn Cytopathol (2008) 0.77
Correction: TCTP is an androgen-regulated gene implicated in prostate cancer. PLoS One (2015) 0.75
Genome profiles of bilateral dysgerminomas, a unilateral gonadoblastoma, and a metastasis from a 46, XY phenotypic female. Hum Pathol (2003) 0.75
A camera support for operating theatre videography. J Vis Commun Med (2012) 0.75
Genomic imbalances in endometrial adenocarcinomas - comparison of DNA ploidy, karyotyping and comparative genomic hybridization. Mol Oncol (2011) 0.75
Fifteen-year mortality after radical prostatectomy: which factors are available for patient counselling? Scand J Urol (2013) 0.75